Sixth Wave Affinity (TM) unit ships from the manufacturer

News and research before you hear about it on CNBC et al. Claim your 1-week free trial for StreetInsider Premium here.

Halifax, Nova Scotia – (Newsfile Corp. – October 5, 2021) – Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth wave“,”SIXW“or the”Society“) is pleased to announce the shipment of its Affinity System” (the “System”) for the purification of cannabinoids from its subcontractor, Advanced Extraction Systems Inc (“AESI“). The wet tests were performed at AESI and the unit was shipped to the SIXW lab for final setup prior to delivery to Green Envy Extracts (“Green envy“).

We are very happy to continue our collaboration with Sixth Wave on the launch of the Affinity system.“says Amato Spagnoletti, director of Green Envy.”As a growing multi-state cannabis operator, we believe our respective technological approaches will bring significant technical and business benefits and results as we order the first Affinity system with Sixth Wave and with our plan to bring it online. Affinity units in Michigan, Massachusetts and Oregon. , and other locations to be announced in the coming months,” he added.

Once delivered, the system will undergo an on-site commissioning / optimization process at Green Envy. After the confirmatory test period, the system is able to process approximately 6 kg of high purity final distillate every 10 hours of operation. A larger system is expected to be delivered in December 2021. The larger system will be able to produce a finished distillate of approximately 14 kg / 10 hours of operation or more than 30 kg / day, which exceeds the initial target of 20 kg. / company day.

As noted by John Cowan, COO of Sixth Wave, “The launch of this smaller system provides Sixth Wave with a fast track to ensure that every major design component performs as intended and that improvements are incorporated into the delivery of larger production units. The smaller system will be used to serve new customers and support the company’s quality improvement program. As an example, the company is poised to finalize SOPs for processing high CBD hemp extracts and may already meet Canadian regulatory requirements for reduced THC levels. This includes promising data indicating that THC compliant products for the United States are also possible.

About the sixth wave

Sixth Wave is a nanotechnology company with patented technologies that focus on the extraction and detection of target substances at the molecular level using highly specialized Molecular Footprint Polymers (PIMs). The Company is in the process of commercially deploying its Affinity “cannabinoid purification system,” as well as IXOS®, a range of extraction polymers for the gold mining industry. The Company is also in the development phase of a rapid diagnostic test for viruses under the label Accelerated MIPs (AMIPS “).

Sixth Wave can design, develop and market MIP solutions in a wide range of industries. The company focuses on highly relevant nanotechnology architectures for the detection and separation of viruses, biogenic amines and other pathogens, for which the company has products at various stages of development.

For more information on Sixth Wave, please visit our website at:

“Jonathan Gluckman”
Jonathan Gluckman, Ph.D., President and CEO

For more information, please contact the Company:
Telephone: (801) 582-0559
Email: [email protected]

Cautionary Notes

This press release includes certain statements that may be considered “forward-looking statements”, including possible statements regarding the intended use of the products and the performance of the IXOS.®, Affinity “, and AMIPs”. All statements contained in this press release, other than statements of historical fact, which deal with future events or developments that the Company expects, are forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance, and actual events or developments may differ materially from those of the forward-looking statements. These forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the actual performance and financial results of the Company for future periods to differ materially from any projection of future performance or results expressed or implied. by these forward-looking statements. In particular, the successful development and commercialization of the IXOS®The technologies, Affinity “or AMIP” are subject to the risk of failure, uncertainty of medical product development, uncertainty of timing or availability of required regulatory approvals, lack of history of development of products for certain applications and the need for additional capital to carry out product development activities. The ability to tailor affinity “to production levels cannot be proven until the first unit is deployed to an authorized producer who can provide the necessary input product to prove large-scale operation. The value of any product ultimately developed could be adversely affected if the patents are The Company has not yet sought regulatory approval for the use of this product from a regulatory body.

To view the source version of this press release, please visit

Source link

Comments are closed.